MC1R is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-08. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Cyproheptadine is a potent antihistamine or inverse agonist of the histamine H1 receptor. It also has anticholinergic, antiserotonergic, antidopaminergic, and local anesthetic activities. In one study, cyproheptadine had about the same affinity for the serotonin 5-HT2A and 5-HT2B receptors as for the histamine H1 receptor, about 8-fold selectivity for the histamine H1 receptor over the serotonin 5-HT2C receptor, about 2- to 8-fold selectivity for the H1 receptor over the muscarinic acetylcholine receptors, and about 4- to 52-fold selectivity for the histamine H1 receptor over the dopamine receptors. The drug shows lower affinity for α-adrenergic receptors and little to no affinity for the monoamine transporters. Of the serotonin receptors, it is an especially potent antagonist of the 5-HT2 receptors. This is thought to underlie its effectiveness in the treatment of serotonin syndrome. However, it is possible that blockade of 5-HT1 receptors may also contribute to its effectiveness in serotonin syndrome. Cyproheptadine has been reported to block 85% of 5-HT2 receptors in the human brain at a dose of 4 mg three times per day (12 mg/day total) and to block 95% of 5-HT2 receptors in the human brain at a dose of 6 mg three times per day (18 mg/day total) as measured with positron emission tomography (PET). The most widely used dose of cyproheptadine for serotonin syndrome has been said to be 4 mg, though doses of up to 16 mg have been used.
Around the time, an expert concludes that "AI art is everywhere right now", with even experts not knowing what it will mean, a news outlet establishes that "AI-generated art booms" and reports about issues of copyright and automation of professional artists, a news outlet investigates how online communities (e.g. their rules) confronted with many such artworks react, a news outlet raised concerns over deepfakes, a magazine highlights possibilities of enabling "new forms of artistic expression", an editorial notes that it may be seen as a welcome "augmentation of human capability". Moreover, additional functionalities – such as enabling the use of user-provided concepts (like an object or a style) learned from few images for novel personalized art generated from the associated word/s (2 Aug) or expanding beyond the borders of artistic images in the same style (31 Aug) – are reported. On 22 August, Stable Diffusion is released as free and open source software.
The development of the APCI interface for LC–MS started with Horning and collaborators in the early 1973. However, its commercial application was introduced at the beginning of the 1990s after Henion and collaborators improved the LC–APCI–MS interface in 1986. The APCI ion source/ interface can be used to analyze small, neutral, relatively non-polar, and thermally stable molecules (such as steroids, lipids, and fat soluble vitamins). These compounds are not well ionized using ESI. In addition, APCI can also handle mobile phase streams containing buffering agents. The liquid from the LC system is pumped through a capillary and there is also nebulization at the tip, where a corona discharge takes place. First, the ionizing gas surrounding the interface and the mobile phase solvent are subject to chemical ionization at the ion source. Later, these ions react with the analyte and transfer their charge. The sample ions then pass through small orifice skimmers by means of ion-focusing lenses. Once inside the high vacuum region, the ions are subject to mass analysis. This interface can be operated in positive and negative charge modes and singly-charged ions are mainly produced. APCI ion source can also handle flow rates between 500 and 2000 μl/min and it can be directly connected to conventional 4.6 mm ID columns.
Sources: en.wikipedia.org
==== Cognitive behavioral therapy ==== Cognitive behavioral therapy (CBT) is a form of psychosocial intervention that systematically evaluates thoughts, feelings, and behaviors about a problem and works to develop coping strategies to work through those problems. This intervention has demonstrated success in many psychiatric conditions (e.g., depression) and substance use disorders (e.g., tobacco). The use of CBT alone for OUD has declined due to lack of efficacy, and many rely on medication therapy or medication therapy with CBT, since both were found to be more efficacious than CBT alone. CBT has been shown to be more successful in relapse prevention than treatment of ongoing drug use. It is particularly known for its durability.
=== Legal status === Pivekimab sunirine was approved for medical use in the United States in May 2026. The US Food and Drug Administration granted the application for pivekimab sunirine priority review, breakthrough therapy, and orphan drug designations.
== Clinical significance == Leukotrienes, which require the FLAP protein to be synthesized, have an established pathological role in allergic and respiratory diseases. Animal and human genetic evidence suggests they may also have an important role in atherosclerosis, myocardial infarction, and stroke. The structure of FLAP provides a tool for the development of novel therapies for respiratory and cardiovascular diseases and for the design of focused experiments to probe the cell biology of FLAP and its role in leukotriene biosynthesis.
Sources: en.wikipedia.org
NMR quantum computing uses the spin states of nuclei within molecules as qubits. NMR differs from other implementations of quantum computers in that it uses an ensemble of systems; in this case, molecules.
Sex hormones, which influence sex differences and support puberty and reproduction. These hormones include androgens, estrogens, and progestogens. Corticosteroids, including most synthetic steroid drugs, with natural product classes the glucocorticoids (which regulate many aspects of metabolism and immune function) and the mineralocorticoids (which help maintain blood volume and control renal excretion of electrolytes) Anabolic steroids, natural and synthetic, which interact with androgen receptors to increase muscle and bone synthesis. In popular use, the term "steroids" often refers to anabolic steroids.
The first humans to form substantial settlements in what is now Knoxville arrived during the Woodland period (c. 1000 B.C. – 1000 A.D). Knoxville's two most prominent prehistoric structures are Late Woodland period burial mounds, one located along Cherokee Boulevard in Sequoyah Hills, and the other located along Joe Johnson Drive on the University of Tennessee campus. Substantial Mississippian period (c. 1100–1600 A.D.) village sites have been found at Post Oak Island (along the river near the Knox-Blount line), and at Bussell Island (near Lenoir City). The Spanish expedition of Hernando de Soto is believed to have traveled down the French Broad Valley and visited the Bussell Island village in 1540 en route to the Mississippi River. A follow-up expedition led by Juan Pardo may have visited village sites in the Little Tennessee Valley in 1567. The records of these two expeditions suggest the area was part of a Muskogean chiefdom known as Chiaha, which was subject to the Coosa chiefdom further to the south. By the 18th century, the Cherokee had become the dominant tribe in the East Tennessee region, although they were consistently at war with the Creeks and Shawnee. The Cherokee people called the Knoxville area kuwanda'talun'yi, which means "Mulberry Place." Most Cherokee habitation in the area was concentrated in the Overhill settlements along the Little Tennessee River, southwest of Knoxville.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.